3 completed, 1 unknown. 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Hepatitis Delta Virus: new trials by email Literature Review of Hepatitis Delta Virus trials Research Report on Hepatitis Delta Virus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants ABI-6250, Placebo - Hepatitis Delta Virus, Hepatitis D | Phase 1 | Completed | Assembly Biosciences | 40 | 2025-01-31 | 2025-12-04 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV Peginterferon Lambda-1a - Hepatitis Delta Virus | Phase 3 | Unknown | Eiger BioPharmaceuticals | 150 | 2021-12-21 | 2023-08-25 |
| Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Lonafarnib, Ritonavir, PEG IFN-alfa-2a - Hepatitis Delta Virus | Phase 3 | Completed | Eiger BioPharmaceuticals | 407 | 2018-12-01 | 2023-04-14 |
| Liver Fibrosis in Zambian HIV-HBV Co-infected Patients Anti-HIV Agents - Human Immunodeficiency Virus, HBV | Completed | University of Alabama at Birmingham | 349 | 2015-10-01 | 2026-07-02 |
Hepatitis D (4) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Hepatocellular (1) · Hepatitis, Alcoholic (1) · Liver Cirrhosis (1)
Digestive System Diseases (4) · Hepatitis (4) · Hepatitis, Viral, Human (4) · Infections (4) · Liver Diseases (4) · RNA Virus Infections (4) · Virus Diseases (4) · Adenocarcinoma (1) · Alcohol-Induced Disorders (1) · Alcohol-Related Disorders (1) · Blood-Borne Infections (1) · Carcinoma (1) · Chemically-Induced Disorders (1) · Communicable Diseases (1) · Digestive System Neoplasms (1)
Anti-HIV Agents (1) · Ritonavir (1) · lonafarnib (1) · peginterferon alfa-2a (1) · peginterferon lambda-1a (1)
Eiger BioPharmaceuticals (2) · Assembly Biosciences (1) · University of Alabama at Birmingham (1)
Belgium (2) · Bulgaria (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Moldova (2) · New Zealand (2) · Romania (2) · Spain (2) · Turkey (Türkiye) (2) · United States (2) · Canada (1) · Georgia (1) · Greece (1)
K01TW009998 (1)